Update on the role of rituximab in kidney diseases and transplant

Abstract

Rituximab could be a beneficial drug in certain renal diseases and for complications related to kidney transplantation where conventional treatment has not been successful.

10-Летний Личный Опыт Применения Ритуксимаба У Нефрологических Пациентов

“…Dmytro D. Ivanov, MD, PhD, Professor, Head of the Department of nephrology and renal replacement therapy, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine; e-mail: drivanovdd@gmail.com; ORCID iD: orcid.org/0000-0003-2609-0051 Olena O. Dyadyk, MD, PhD, Professor, Head of the Department of pathologic and topographic anatomy, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine Svitlana O. Rotova, MD, PhD, Professor, Head of the Department of nephrology and renal replacement therapy, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine Mariia Ivanova, PhD researcher, Universita di Milano-Bicocca, Milan, Italy; ORCID iD: orcid.org/0000-0002-7636-1000 Иванов Д.Д. 1…”

Застосування Імунобіологічних Лікарських Препаратів На Основі Моноклональних Антитіл У Нефрологічній Практиці

“…Это также не представляется возможным из-за иммунизации людей in vivo различными антигенами [19] Применение ритуксимаба при некоторых заболеваниях почек и пересадке почек представлено в табл. 2 [30].…”

Glomerulonephritis, Pathogenetic Mechanisms and Therapeutic Options: An Overview

“…Subsequently, it was recognized for the treatment of rheumatoid arthritis and vasculitis, and then its use has been indicated for other diseases. In nephrology rituximab has been used in some of both primitive and secondary glomerulonephritis and in the prevention of transplant rejection [47][48][49]. Membranous glomerulonephritis is one the most common causes of the nephrotic syndrome in non-diabetic adults and its treatment is still controversial.…”

“…On the other hand, despite all the drugs available, there are some patients who do not respond to therapies and who progress in the severity of their clinical condition [45]. Therefore, in this group of patients, it seemed appropriate the use of Rituximab, based on the most recent evidences [48,49]. However, because of the great variability of the lupus disease and the absence of large controlled trials, clear indications for rituximab in lupus are still lacking.…”